Basal insulin supplementation in Type 1 diabetic children: A long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin

Journal of Endocrinological Investigation

Volumn 30, Issue 7, 2007, Pages 572-577

  Schiaffini, R ^a   Patera, P I ^a   Bizzarri, C ^a   Ciampalini, P ^a   Cappa, M ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Continuous subcutaneous insulin infusion; Glargine insulin; HbA1c; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; MALE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM;

EID: 35348847876     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346351     Document Type: Article

References (36)

1. Pickup JC, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002, 25: 593-8.
2. Mack-Fogg JE, Orlowski CC, Jospe N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatr Diabetes 2005, 6: 17-21.
3. Low KG, Massa L, Lehman D, Olshan JS. Insulin pump use in young adolescents with type 1 diabetes: a descriptive study. Pediatr Diabetes 2005, 6: 22-31.
4. Pickup JC, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002, 324: 705.
5. 1c levels across all age groups. Pediatr Diabetes 2002, 3: 10-5.
6. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005, 28: 1277-81.
7. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49: 2142-8.
8. Kuer-zel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003, 19: 34-40.
9. Reinhart L, Panning CA. Insulin glargine: a new long-acting insulin product. Am J Health Syst Pharm 2002, 59: 643-9.
10. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001, 109 (Suppl 2): S317-32.
11. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984, 7: 188-99.
12. Brange J, Langkjaer L. Insulin formulation and delivery. Pharm Biotechnol 1997, 10: 343-409.
13. Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investiagtor Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000, 23: 1137-42.
14. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000, 23: 639-43.
15. Hamann A, Matthaei S, Rosak C, Silvestre L; HOE6901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003, 26: 1738-44.
16. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15: 369-76.
17. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26: 799-804.
18. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimes using insulin lispro in type 1 diabetic patients on intensified treatment. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000, 23: 1232-5.
19. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallelgroup, 24-week study. Diabetes Care 2003, 26: 2598-603.
20. Schiffrin AD, Desrosiers M, Aleyassine H, Belmonte MM. Intensified insulin therapy in the type 1 diabetic adolescent: a controlled trial. Diabetes Care 1984; 7: 107-13.
21. Kanc K, Jannssen MMJ, Keulen ETP, et al. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia 1998, 41: 322-9.
22. Fahlen M, Eliasson B, Oden A. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabet Med 2005, 22: 382-6.
23. Schiaffini R, Ciampalini P, Spera S, Cappa M, Crinò A. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabet Metab Res Rev 2005, 21: 347-52.
24. King AB, Armstrong D. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. Diabetes Care 2003, 26: 1322.
25. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003, 26: 1321-2.
26. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003, 63: 1743-78.
27. The Expert Committee on the Diagnosis-and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20: 1183-97.
28. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160-7.
29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329: 977-86.
30. Nordfeldt S, Ludvigsson J. Adverse events in intensively treated children and adolescents with type 1 diabetes. Acta Paediatr 1999, 88: 1184-93.
31. Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001, 14: 292-304.
32. Schade DS, Valentine V. To pump or not to pump. Diabetes Care 2002, 25: 2100-2.
33. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003, 5: 801-6.
34. Armstrong DU, King AB. Basal insulin: continuous glucose monitoring reveals less overnight hypoglycemia with continuous subcutaneous insulin infusion than with glargine (Abstract). Diabetes 2002, 51 (Suppl 2): A92.
35. Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27: 1554-8.
36. Cherubini V, Iannilli A, Iafusco D, et al. Premeal insulin treatment during basal-bolus regimen in young children with type 1 diabetes. Diabetes Care 2006, 29: 2311-2.